华润三九 (000999)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

ASZ

Tags

300ESG Index300 Non-Cyclical IndexQFII Heavy PositionsMid Cap ValueCSI 200 IndexCSI Central State-Owned Enterprises IndexGeneric DrugsNorthbound Heavy PositionsFace Mask ProtectionGuozheng Value IndexGuozheng Growth IndexCentral State-Owned Enterprises 100 IndexEmerging Markets IndexPrivate HospitalsSocial Security HeavyHigh-Performing StocksRestructuring StocksNorthbound Connect Heavy PositionsNon-Cyclical StocksShenzhen Main Board 50 IndexShenzhen ConnectSZSE 100 IndexSZSE 300 IndexSZSE Value IndexSZSE Growth IndexCSFC HoldingsPharma & BiotechChinese Med. IISZSE Defensive 50 IndexStable Growth IndexConsumer Services IndexSZSE Enterprises Composite IndexGreater Bay Area IndexSZSE Medicine Equal Weight IndexInnovation Demonstration IndexInnovation Engine IndexSZSE 100 Equal Weight IndexCSI Emerging Industries IndexShenzhen A-Share Pharmaceutical IndexState-owned Central Enterprises 50 IndexBOC International CSI 300 ESG IndexCSI 100 Low Volatility IndexCS High Dividend Yield IndexCSI All-share Pharmaceutical Sector IndexSZSE Emerging Industries IndexSZSE 1000 IndexSZSE 300 Return IndexCSSW Health IndexCSI 1000 Growth IndexSZSE Component Index ReturnCSI 300 Equal Weight IndexCSI 300 ESG IndexLarge & Mid-cap IndexShanghai-Hong Kong-Shenzhen 300 IndexCNI 1000 IndexXingyin Wealth Management Balanced 300 IndexCR Foundation IndexCentral Enterprises Innovation IndexCSSW Silk Road IndexSZSE Performance IndexOrient Securities Value IndexState-owned Enterprises Belt and Road IndexChengtong Central Enterprises Dividend IndexInfluenza/MaskNew Virus PreventionCOVID-19 PreventionMSCIFTSE Russell ConceptHuijin ConceptInsurance Heavy HoldingsHigh DividendCSI 300 Non-cyclical IndexPension Industry IndexSHS Greater Bay Area IndexSZSE Selected IndexSZSE Central Enterprises IndexSZSE Responsibility IndexCSI 300 Shenzhen Market IndexSZSE Technology IndexEmerging Industries Composite IndexSZSE 100 Return IndexManufacturing IndexSZSE ChiNext 100 IndexSustainable Development IndexCSRC Central Enterprises Composite IndexCSI 300 Growth IndexSecurities Times Value 100 IndexSZSE Pharmaceutical IndexDividend Quality IndexCSI 800 IndexCS Pharmaceutical TI Index100 Performance IndexESG 100 IndexCSI 300 Preferred IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexCNI 300 IndexCCTV 500 IndexCS Pearl River Delta IndexCSI 300 USD (CNH) IndexHua Xia Bank ESG IndexCS Pharmaceutical Innovation IndexChina United Quality Growth IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexSZSE Low Volatility IndexCSI All-share Pharmaceutical IndexCSI 300 USD IndexSZSE Pharmaceutical 50 IndexSZSE 300 Equal Weight IndexCSI Pharmaceutical IndexZhaoyang 100 IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexCSI 300 Pharmaceutical IndexCSI 700 IndexAH Economic Blue-chip IndexMid-small Cap IndexSZSE Fundamental 200 IndexPharmaceutical 50 IndexPharmaceutical 50 Strategy IndexSZSE 200 Return IndexSZSE 200 IndexMid-cap Low Volatility IndexStructural Adjustment IndexCICC 300 IndexCentral Enterprises Modern Industry IndexESG 300 IndexCR New Momentum IndexChina Economic Index GDPJuchao Mid-cap IndexCSI 1000 Value IndexSZSE Fundamental 120 IndexFundamental 600 IndexCSI 300 Growth Innovation IndexStrategic Emerging Industries 100 IndexGuangdong

K-Line Chart

No K-line data available

Company NameChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Listing Date2000-03-09
Issue Price8.45RMB
Registered Capital166421.785810k RMB
Legal RepresentativeWu Wenduo
Registered AddressNo. 1 Guanqing Road, Guanlan High-Tech Park, Guanhu Street, Longhua District, Shenzhen City, Guangdong Province
IndustryTraditional Chinese Medicine II
Main BusinessBusinesses including the development, production, and sales of pharmaceuticals, as well as healthcare services.
Company ProfileChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a large state-controlled listed pharmaceutical company primarily engaged in the R&D, production, sales, and related health services of pharmaceutical products. It is a "Top 100 Most Valuable Companies" among China's Main Board listed companies. The company has repeatedly been honored with titles such as "Golden Bull Top 100," "Top 100 Most Valuable Companies," "Top 100 Most Respected Listed Companies by Investors," "Most Growth Potential Listed Company," "Top 20 Most Competitive Pharmaceutical Listed Companies in China," "Top 10 Most Investable Pharmaceutical Listed Companies in China," "Shenzhen Stock Exchange Index Best Investor Relations Listed Company," and "Shenzhen Stock Exchange Index High-Performance Listed Company."

Stock Details

1. Key Indicators

  • Total Shares(W): 166421.79
  • Circulating A-Shares(W): 166269.40
  • Earnings Per Share(RMB): 1.4200
  • Net Assets Per Share(RMB): 12.6878
  • Operating Revenue(W RMB): 2198640.40
  • Total Profit(W RMB): 343060.99
  • Net Profit Attributable to Parent(W RMB): 235282.70
  • Net Profit Growth Rate(%): -20.51
  • Weighted Return on Equity(%): 11.4700
  • Operating Cash Flow Per Share(RMB): 1.7580
  • Undistributed Profit Per Share(RMB): 10.3685
  • Capital Reserve Per Share(RMB): 0.8448

2. Main Business

The main business covers:

  • Development, production, and sales of pharmaceuticals
  • Cultivation of Chinese medicinal herbs
  • Development, transfer, and services of related technologies
  • Import business of machinery, equipment, and raw materials required for production
  • Export of self-produced products
  • Wholesale of prepackaged food (excluding reheating)
  • Development and sales of cosmetics and Class I medical devices
  • Leasing of self-owned properties and motor vehicle parking services

3. Company Basic Information

  • Company Name: China Resources Sanjiu Medical and Pharmaceutical Co., Ltd.
  • Listing Date: 2000-03-09
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 1 Guanqing Road, Guanlan High-tech Park, Guanhu Street, Longhua District, Shenzhen City, Guangdong Province
  • Website: www.999.com.cn
  • Company Profile: The company was established as a joint-stock company, with Shenzhen Sanjiu Pharmaceutical Co., Ltd. as the main sponsor, jointly initiated with Sanjiu Enterprise Group, Shenzhen Jiu Xian Bioengineering Co., Ltd., Shenzhen Xiandaming Trading Co., Ltd., and Huizhou Renxing Industrial and Trade Co., Ltd. Shenzhen Sanjiu Pharmaceutical Co., Ltd. and Sanjiu Enterprise Group contributed net assets and cash, converted into 552 million state-owned legal person shares. The other three sponsors contributed cash, totaling 1 million shares. The company's total share capital was 553 million shares. After the public issuance of 200 million ordinary shares from November 11 to 12, 1999, the company's total share capital reached 753 million shares.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 China Resources Pharmaceutical Holding Co., Ltd. General Legal Person 105214.27 63.28
2 China Chengtong Holdings Group Co., Ltd. Special Legal Person 3387.22 2.04
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 3378.11 2.03
4 Huatai-PineBridge CSI 300 ETF Fund 1145.40 0.69
5 E Fund Yu Xiang Return Bond Securities Investment Fund Class A Fund 846.16 0.51
6 E Fund CSI 300 Healthcare ETF Fund 837.33 0.50
7 E Fund CSI 300 ETF Fund 821.87 0.49
8 TEMASEK FULLERTON ALPHA PTE LTD QFII 793.03 0.48
9 Guoxin Investment Co., Ltd. Special Legal Person 647.28 0.39
10 ChinaAMC CSI 300 ETF Fund 613.34 0.37

5. Concept Sectors

  • Photovoltaic
  • Generic Drugs
  • Mask Protection
  • Green Power
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • QFII Heavy Holdings
  • Restructuring Stocks
  • Northbound Heavy Holdings
  • Mainland-HK Stock Connect Heavy Holdings
  • Non-Cyclical Stocks
  • Central Enterprises 100
  • SZSE Value
  • Mid-Cap Growth
  • Mid-Cap Value
  • SZSE 100
  • SZSE 300
  • SZSE Dividend
  • SZSE Growth
  • SZSE Growth
  • CSI 300
  • CSI 200
  • CSI 300 Non-Cyclical
  • CSI Central Enterprises
  • CSI 300 ESG
  • Emerging Composite Index
  • Pearl River Delta
  • SZSE Main Board 50

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information